Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a wearable sensor replace fingerstick checks for sepsis patients in the ICU?

NCT ID NCT07686939

Disease control Sponsor: Taizhou Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This trial tests whether a continuous glucose monitor (CGM) — a small sensor worn on the arm — can help manage blood sugar levels more effectively than standard fingerstick checks in critically ill sepsis patients. Sepsis patients often have unstable blood sugar, which can lead to complications. The study compares the CGM's accuracy, how well it helps staff follow treatment guidelines, and whether it saves time. If it works, CGM could offer a more reliable and less labor-intensive way to monitor glucose in the ICU.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
FreeStyle Libre II continuous glucose monitor (device)
What this could lead to
If successful, CGM could become a standard tool in ICUs for managing blood sugar in sepsis patients, potentially reducing complications and nursing workload.
What could go wrong
This is a small, early-stage trial (60 patients) focused on accuracy and feasibility, not long-term outcomes. CGM may not prove reliable enough or improve patient survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

60 people

The number who actually took part.

Started

Jan 2023

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Critically ill adult patients (≥18 years) with sepsis (infection + SOFA increase ≥2) admitted to the ICU. Total 60 patients (mean age 75.6 years; 42 male/18 female), with or without diabetes. Excludes those with sensor contraindications, non-cooperation, or anticipated incomplete follow-up.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years. * Confirmed infection accompanied by an increase in Sequential Organ Failure Assessment (SOFA) score of ≥ 2 points. * Written informed consent provided by the patient or legally authorized representative. Exclusion Criteria: * Discharge against medical advice or transfer to another facility before study completion, leading to incomplete data. * Non-cooperation with study procedures. * Contraindications to the application of the flash glucose monitoring sensor (e.g., severe skin disease at insertion site, known allergy to sensor components).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glycemic control are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hyperglycemia infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glycemic control Hyperglycemia Sepsis

Contacts and locations

Locations

  • Taizhou Municipal Hospital

    Taizhou, Zhejiang, 318000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.